➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Baxter
Express Scripts
Moodys
Colorcon

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 8,541,461

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,541,461
Title:Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
Abstract: The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R.sup.1 and NR.sup.2R.sup.3 and a maximum chain length of 4 atoms extending between E and NR.sup.2R.sup.3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom .alpha. with respect to the NR.sup.2R.sup.3 group and provided that the oxo group when present is located at a carbon atom .alpha. with respect to the NR.sup.2R.sup.3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R.sup.1 is an aryl or heteroaryl group; and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the claims. Also provided are patient packs, pharmaceutical kits and packs and compositions containing the combinations, methods for preparing the combinations and their use in combination therapy as anticancer agents. ##STR00001##
Inventor(s): Thompson; Neil Thomas (Cambridge, GB), Boyle; Robert George (Cambridge, GB), Collins; Ian (Redhill, GB), Garrett; Michelle Dawn (Walton-on-Thames, GB), Lyons; John Francis (Cambridge, GB), Thompson; Kyla Merriom (Cambridge, GB)
Assignee: Astex Therapeutics Limited (Cambridge, GB) The Institute of Cancer Research Royal Cancer Hospital (London, GB) Cancer Research Technology Limited (London, GB)
Application Number:11/993,823
Patent Claims:see list of patent claims

Details for Patent 8,541,461

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Astex Therapeutics Limited (Cambridge, GB) The Institute of Cancer Research Royal Cancer Hospital (London, GB) Cancer Research Technology Limited (London, GB) 2039-02-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Astex Therapeutics Limited (Cambridge, GB) The Institute of Cancer Research Royal Cancer Hospital (London, GB) Cancer Research Technology Limited (London, GB) 2039-02-26 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Astex Therapeutics Limited (Cambridge, GB) The Institute of Cancer Research Royal Cancer Hospital (London, GB) Cancer Research Technology Limited (London, GB) 2039-02-26 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Astex Therapeutics Limited (Cambridge, GB) The Institute of Cancer Research Royal Cancer Hospital (London, GB) Cancer Research Technology Limited (London, GB) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Johnson and Johnson
Mallinckrodt
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.